{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:52:31Z","timestamp":1776041551968,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T00:00:00Z","timestamp":1551052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.vaccine.2019.02.024","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T21:39:21Z","timestamp":1550785161000},"page":"1819-1826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial"],"prefix":"10.1016","volume":"37","author":[{"given":"Fatma","family":"Doener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henoch S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyvan","family":"Tadjalli-Mehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Daehling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven D.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariola","family":"Fotin-Mleczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Gnad-Vogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2019.02.024_b0005","doi-asserted-by":"crossref","first-page":"C25","DOI":"10.1016\/j.vaccine.2010.07.021","article-title":"Unmet needs in modern vaccinology: adjuvants to improve the immune response","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.024_b0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1920 to 2015 and beyond","volume":"3","author":"Di Pasquale","year":"2015","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2019.02.024_b0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2019.02.024_b0020","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14760584.2013.811208","article-title":"The use of Toll-like receptor 7\/8 agonists as vaccine adjuvants","volume":"12","author":"Vasilakos","year":"2013","journal-title":"Exp Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2019.02.024_b0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/vaccines2020323","article-title":"Immune adjuvant effect of molecularly-defined Toll-like receptor ligands","volume":"2","author":"Toussi","year":"2014","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2019.02.024_b0030","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386: 31\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(15)60721-8.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"10.1016\/j.vaccine.2019.02.024_b0035","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"issue":"5663","key":"10.1016\/j.vaccine.2019.02.024_b0040","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"issue":"5663","key":"10.1016\/j.vaccine.2019.02.024_b0045","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.vaccine.2019.02.024_b0050","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.4049\/jimmunol.1601129","article-title":"A new RNA-based adjuvant enhances virus-specific vaccine responses by locally triggering TLR- and RLH-dependent effects","volume":"198","author":"Ziegler","year":"2017","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.02.024_b0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ijc.29402","article-title":"A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile","volume":"137","author":"Heidenreich","year":"2015","journal-title":"Int J Cancer"},{"issue":"49\u201350","key":"10.1016\/j.vaccine.2019.02.024_b0060","first-page":"425","article-title":"WHO position paper","volume":"82","author":"Rabies vaccines","year":"2007","journal-title":"Releve Epidemiol Hebd"},{"key":"10.1016\/j.vaccine.2019.02.024_b0065","unstructured":"WHO Expert Committee on Biological Standardization, 64th report. Annex 2. Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines. Available at: http:\/\/www.who.int\/biologicals\/areas\/vaccines\/TRS_987_Annex2.pdf?ua=1."},{"issue":"2","key":"10.1016\/j.vaccine.2019.02.024_b0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpeds.2007.02.059","article-title":"Primary immunization of premature infants with gestational age <35 weeks: cardiorespiratory complications and C-reactive protein responses associated with administration of single and multiple separate vaccines simultaneously","volume":"151","author":"Pourcyrous","year":"2007","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.vaccine.2019.02.024_b0075","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00431-013-1946-2","article-title":"Inflammatory responses to hepatitis B virus vaccine in healthy term infants","volume":"172","author":"Celik","year":"2013","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2019.02.024_b0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2796.2010.02285.x","article-title":"Inflammation-related effects of adjuvant influenza A vaccination on platelet activation and cardiac autonomic function","volume":"269","author":"Lanza","year":"2011","journal-title":"J Intern Med"},{"issue":"30","key":"10.1016\/j.vaccine.2019.02.024_b0085","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.vaccine.2013.04.063","article-title":"Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers","volume":"31","author":"Hopkins","year":"2013","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2019.02.024_b0090","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1016\/j.vaccine.2010.10.009","article-title":"Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults","volume":"28","author":"Treanor","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.024_b0095","doi-asserted-by":"crossref","unstructured":"Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33(4):492\u2013503. https:\/\/doi.org\/ 10.1016\/j.immuni.2010.10.002.","DOI":"10.1016\/j.immuni.2010.10.002"},{"issue":"1","key":"10.1016\/j.vaccine.2019.02.024_b0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00262-016-1923-5","article-title":"Immunological effects of a novel RNA-based adjuvant in liver cancer patients","volume":"66","author":"Circelli","year":"2017","journal-title":"Cancer Immunol Immunother CII"},{"issue":"1","key":"10.1016\/j.vaccine.2019.02.024_b0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00262-015-1728-y","article-title":"HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma","volume":"65","author":"Buonaguro","year":"2016","journal-title":"Cancer Immunol Immunother CII"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.02.024_b0110","first-page":"172","volume":"6","author":"Heinzerling","year":"2018","journal-title":"J Immunotherap Canc"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19302191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19302191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:31:13Z","timestamp":1759401073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19302191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":22,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0264410X19302191"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}